Tykerb in combination with capecitabine is indicated to treat advanced or metastatic breast cancer patients whose tumors overexpress HER2 and who were previously treated with anthracycline, a taxane and trastuzumab.
Eddingpharm chairman and chief executive officer Xin Ni said the agreement with GSK on Tykerb is an important milestone of China’s pharmaceutical industry in addition to the company’s business development history.
"Eddingpharm is committed to bringing quality medical products into China, providing a growing range of treatment tools for physicians and offering better therapeutic options for patients," Ni added.
"This partnership with GSK helps us fully leverage our rich market experience and mature marketing platforms to open a fast track for Tykerb’s China launch."
Small molecular reversible inhibitor of tyrosine kinase (TKI), Lapatinib, has effective absorption upon oral administration.